Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, has announced that it has raised US$150 million in Series B funding. Led by Cormorant Asset Management, the round included an investment from Goldman Sachs Asset Management and existing investors.Latham & Watkins LLP advised Goldman Sachs in the financing with a deal team led by Silicon Valley partner Saad Khanani, with associates Omar Ammash, Autumn Schmidt and Erica Kucharski. Advice was also provided on healthcare matters by Washington, D.C. partners Ben Haas, and Jason Caron, with Washington, D.C. counsel Chad Jennings; on IP matters by Silicon Valley partner Judith Hasko.
Powered by WPeMatico